<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113434</url>
  </required_header>
  <id_info>
    <org_study_id>19-016271</org_study_id>
    <secondary_id>R01HL148054</secondary_id>
    <nct_id>NCT04113434</nct_id>
  </id_info>
  <brief_title>Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome</brief_title>
  <acronym>LEOPARDS</acronym>
  <official_title>Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akron Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital and Health System Foundation, Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Barnabas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of the study is to risk stratify pediatric Acute Respiratory Distress
      Syndrome (ARDS) patients and to identify sub-phenotypes with shared biology in order to
      appropriately target therapies in future trials. This is a prospective, multicenter study of
      500 intubated children with ARDS, with planned blood collection within 24 hours of ARDS onset
      and subsequent measurement of plasma protein biomarkers and peripheral blood gene expression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will measure pre-determined biomarkers with known or suspected association with
      ARDS severity or outcome. Simultaneously, investigators will measure gene expression of
      peripheral blood. Both plasma biomarkers and gene expression profiles will be analyzed using
      various machine learning techniques, including classification and regression tree, latent
      class analysis, and hierarchical clustering with the goal of identifying sub-phenotypes of
      ARDS. These sub-phenotypes will be examined for association with outcome (primary is 28-day
      mortality), and explicitly tested for variation in response to exogenous treatments (e.g.,
      corticosteroids).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>28 Day Mortality in Pediatric ARDS.</measure>
    <time_frame>28 days</time_frame>
    <description>28 day all cause mortality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of two or more endotypes in Pediatric ARDS.</measure>
    <time_frame>Within 24 hours of ARDS onset</time_frame>
    <description>Stratify pediatric ARDS into sub-phenotypes using a known 100-gene expression-based classifier to group subjects according to shared underlying biology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of de novo sub-phenotypes in pediatric ARDS using biomarkers and whole genome transcriptomics of peripheral blood.</measure>
    <time_frame>Within 24 hours of ARDS onset.</time_frame>
    <description>Occurrence of de novo sub-phenotypes in pediatric ARDS using 12 protein biomarkers and whole genome transcriptomics of peripheral blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ventilator-free days at 28 days.</measure>
    <time_frame>28 days</time_frame>
    <description>composite endpoint of days alive and free of mechanical ventilation by day 28.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Infants to adolescents between the ages of 44 weeks and 17.5 years, who are admitted to
        PICU for acute respiratory failure requiring invasive mechanical ventilation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. acute (≤ 7 days of risk factor) respiratory failure requiring invasive mechanical
             ventilation

          2. age &gt; 44 weeks corrected gestational age and &lt; 17.5 years

          3. invasive mechanical ventilation via endotracheal tube

          4. bilateral infiltrates on chest radiograph

          5. oxygenation index (OI) ≥ 4; or oxygen saturation index (OSI) ≥ 5 on 2 consecutive
             measurements at least 4 hours apart but &lt; 24 hours apart

          6. invasively ventilated ≤ 7 days before meeting above radiographic and oxygenation
             criteria

          7. invasive blood drawing access (central venous catheter, arterial catheter, or
             blood-drawing IV)

        Exclusion Criteria:

          1. weight &lt; 3 kilograms

          2. cyanotic congenital heart disease (other than Patent Foramen Ovale (PFO) or Patent
             Ductus Arteriosus (PDA))

          3. tracheostomy at time of screening

          4. invasively ventilated for &gt; 7 days when meet ARDS criteria above

          5. cardiac failure as predominant cause of respiratory failure

          6. primary obstructive airway disease (asthma, bronchiolitis) by judgement of clinician
             as the primary cause of respiratory failure

          7. alternative known chronic lung disease as cause of respiratory failure (cystic
             fibrosis, eosinophilic pneumonia, interstitial pneumonitis, pulmonary hemosiderosis,
             cryptogenic organizing pneumonia)

          8. severe neurologic morbidity not expected to survive &gt; 72 hours

          9. any limitations of care at time of screening

         10. previous enrollment in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>44 Weeks</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadir Yehya, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadir Yehya, M.D.</last_name>
    <phone>215-590-1858</phone>
    <email>yehyan@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Famularo, BA</last_name>
    <email>famularois@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Pearman</last_name>
      <email>rlpearman@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Ioannis Koutroulis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Variety Children's Hospital D/B/A Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatriz Govantes</last_name>
      <email>beatriz.govantes@nicklaushealth.org</email>
    </contact>
    <investigator>
      <last_name>Keith Meyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Children's at Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Ramberg</last_name>
      <email>kramberg@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Courtney Rowan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Asdis Finnsdottir-Wagner, DO</last_name>
      <email>dwagner@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Asdis Finnsdottir-Wagner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shira Gertz, MD</last_name>
      <email>shira.gertz@rwjbh.org</email>
    </contact>
    <investigator>
      <last_name>Shira Gertz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Breton</last_name>
      <email>cb3053@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Danielle Ahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Anthony</last_name>
      <email>hanthony@akronchildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Debbie Giebner</last_name>
      <email>dgiebner@akronchildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ryan Nofziger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Page-Goertz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhonda Jones</last_name>
      <email>rhonda.jones@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Hector Wong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Steele</last_name>
      <email>lisa.steele@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Mark Hall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debbie Spear</last_name>
      <email>dspear@pennstatehealth.psu.org</email>
    </contact>
    <investigator>
      <last_name>Neal Thomas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen T Famularo</last_name>
      <phone>215-590-2964</phone>
      <email>famularois@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Carbonara</last_name>
      <phone>267-425-1383</phone>
      <email>CARBONARA@EMAIL.CHOP.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Nadir Yehya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital / Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debbie Barrera</last_name>
      <email>dxbarrer@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Parag Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sadaf Shad</last_name>
      <email>sshad@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Rainer Gedeit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Specific consent will be obtained to store blood and use data for future research. We will share data with the research community using the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) program at NHLBI, and we will follow suggested guidelines for de-identifying the data (coding of site IDs, conversion of dates to study days).
Pursuant to the NIH policy, all data obtained from this proposal will be made available for research by qualified individuals within the scientific community after publication of the proposed studies. Gene expression data from Aims 2 and 3 will be made available simultaneous with publication of the results of these aims by uploading to the Gene Expression Omnibus. For dissemination of plasma biomarker results and the associated clinical dataset, we will use BioLINCC program at NHLBI, with release of a de-identified dataset with untraceable identifiers within 2 years of publication of the main manuscript.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Gene expression data will be released to Gene Expression Omnibus simultaneously with the publication of the data. Biomarker data will be released within 2 years of publication of the main manuscript.</ipd_time_frame>
    <ipd_access_criteria>We will follow NHLBI's guidelines for accessing BioLINCC data.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT04113434/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

